Inderes’ Disclaimer can be found here. Detailed information about each share actively monitored by Inderes is available on the company-specific pages on Inderes’ website. © Inderes Oyj. All rights reserved.
Read transcripts of webcasts and audiocasts
Read transcripts of webcasts and audiocasts
Disclaimer: This is a machine-generated transcript and may contain inaccuracies.
Good morning. Patrick speaking. And thank you very much for joining us on our quarterly call today. We'll just jump right into it and talk a little bit about our highlights for the quarter. First and foremost, we delivered strong earnings growth in the quarter. We're very pleased about how that developed. And we'll talk a little bit more about where it came from and how it came to be. Um, and as you might recall from the last time we met, we signaled that our organic revenue growth was going to be impacted by the adjustment in the annual order program. Therefore, our organic growth is a bit lower than you might have expected and have seen us achieve in the past. The remaining operating units that we have, the three others, all delivered double-digit organic growth in the quarter. And we also passed a very significant milestone a few weeks ago when we started to trade on the Large Cap market on the Nasdaq Main Market here in Stockholm. It's a very important milestone for us as a publicly traded company. And in general terms and overall, we are very well positioned. We're in an attractive market, and there are some fundamental underlying growth factors there that we really like, and we continue to view positively. And we're also an agile business with an opportunity to steer and change our business, as the world around us is uncertain and changing. With that, let's go and dive a little bit deeper into the numbers. For the quarter, we delivered an 18% revenue growth, reaching €107.5 million. Organic growth ended up being 4%, negatively impacted by the adjustment in the annual order program, which is limited to our MedTech Orthopaedics business in the US. The other segments delivered double-digit growth. Our adjusted EBITDA for the quarter also grew 18% to 28.3 million. Our margins were stable at 26.3. Exactly the same as we had last year. And remember, we consolidated a new MedTech segment here in dental with our iM3 acquisition. At the time we acquired it, it had a lower margin profile than the rest of EMEA. Now turning to our Specialty Pharma business, we experienced another quarter with strong performance, achieving 10% organic growth. Um, and we had growth across all our therapeutic areas. We had significant contributions from our specialty pharmaceuticals and our dermatology part of the business. Uh, we continue to innovate in this part of our business, and we see that the new launches contribute to growth. We had 23 new products that we launched this quarter, and the EBITA continued to grow nicely at 19%. Here, our margin improved from 27.8% to 28.8%, and that was driven predominantly by operational leverage and a positive mix. Returning to MedTech for a moment here, as expected and as we communicated in February, we saw an organic decline for our MedTech business, and it was primarily driven by the annual order program in our Orthopaedics part of the business in the US. Additionally, as we have noted since last summer, we've observed softness in the elective surgery market in the US. So that would be for our business and our hip business there. The other regions that we have, EMEA and APAC, continue to deliver high single-digit growth. Um, and that's up from when we reported in Q4. And we continue to invest in education, especially in the US, to access the untapped opportunity, the untreated animals, and the untrained clinicians so that they can help us expand the addressable market. In the first quarter here, we educated over 1,500 professionals in Orthopaedics. That's about the same as we did in Q4. As you might recall, it was about 1600 back then, and the target for us in 2025 is to return this business to growth, which we're confident that we will be able to do. When we look at it, our margin shows a clear sequential improvement, both year over year. Um, and uh, the consolidation from Q4, we faced that AOP, which has an impact on our margins, and obviously the incorporation of iM3. Uh, at the end of the quarter as well, actually, right after we finished the quarter, we completed our first bolt-on acquisition with Dental Focus that we've welcomed to our family. That's a New Jersey-based company in the northeast part of America with revenues around $3 million. It's a great strategic fit for us. It complements the iM3 portfolio, and it also adds access to a new customer base, predominantly in the northeast of America. So we're very excited to have that team join us. We go to our veterinary services business, another double-digit revenue growth quarter, with phenomenal growth in EBITDA during this quarter. And as we mentioned, we have started to make some investments to grow our business organically. And one of these initiatives was launched in the first quarter, where we introduced DVM Grow, which is a new services platform targeting an untapped market segment in the US. This was launched mid-quarter, and it's an important initiative for our veterinary services business to continue to strengthen our position in America and also tap into a market that we were unable to reach in the past. Our margins improved from 25.4% to 30.3%, and again, it was driven by the growth. Also, we have a positive geographic mix for our vet services business. Now turning to diagnostics. Um, again, uh, for the second consecutive quarter, we delivered double-digit growth here at 16%, driven by our livestock segment. And, um, also, as we have told everybody before, we are continuing to invest in rolling out a product in the companion animal space, which is why our earnings continue to be at the level that they are. So we're making investments in further market growth. And before I let you go through the financials, I want to spend a little bit of time discussing our progress on ESG. First of all, during the quarter, we improved our ESG rating with MSCI from an A to a double A. So we're pleased about the progress that we're making there. Now when we look back and reflect on 2024, we've reduced our emissions and we've strengthened our supplier controls. Both of those are very important focused initiatives that we've been running. We're continuing to work on creating a great place to work at. And we trained all of our employees in business ethics, which is highly important to us. We also educated more than 40,000 veterinary professionals throughout the year, and that is also one of our key metrics and key methods in which we can unlock market growth. We continue to be committed to the ESG strategy and drive positive change in the world. And with that said, I'm going to hand over to Karl-Johan to walk us through some of the details in the financials.
Thank you very much, Patrick, and good morning, everyone. I said, let me give you a walkthrough and some further insights into the group financials for the first quarter. Starting with the income statement, adjusted EBITA in the first quarter was €28.3 million. That's an increase of 18% compared to the same period last year, and it represents a margin of 26.3%. This margin is on par with the same period last year, and that's after including and consolidating iM3 from October 1st. That has a lower margin profile than the rest of the group, and also shows a clear improvement of 290 basis points from the fourth quarter of last year. We report an operating profit of €15.6 million, an increase of 17% from last year's result of €13.4 million. Items affecting comparability clearly impacted the quarter, with a total of €7.0 million. This mainly relates to the continued high level of legal fees in the US patent litigation, with the main hearing taking place in the first quarter, as well as acquisition activities within MedTech. The net financial items of -€7.5 million consist of three main components. Finance expense of -€5.0 million, with an average interest rate of 5.1% during the quarter, which was to some degree offset by €0.5 million interest income. The quarterly discounting impact of -€1.5 million and impact of -€2.8 million from profitability adjustments on contingent considerations, mainly related to adjustment for Australia and France, given good momentum in those two businesses. And lastly, a positive impact of €1.3 million from exchange rate effects on revaluation of debt. The income tax expense for the quarter amounted to €3.4 million, and in total, this results in a profit for the period of €4.7 million, with earnings per share of €0.01 for the quarter. The Q1 cash flow from operating activities reached €17.1 million in the first quarter, showing improved cash generation compared to the same period last year, with a cash conversion of 70% defined as operating cash flow. In relation to EBITA, net working capital amounted to €94.3 million at the end of the quarter, equal to 23% of revenue, which is a decrease from €100.1 million at the end of December, which equaled 25% of revenue. The majority of the decreased working capital is a consequence of higher payables in MedTech and Specialty Pharma. Cash flow from financing activities amounted to -€9.2 million, primarily reflecting the repayment of debt. At the end of the period, net debt amounted to €212.2 million, which is down from €221.9 million at the end of the fourth quarter. External lending is at €206.9 million, which is approximately €10 million less than at the end of the fourth quarter. As we have continued to repay debt, leverage in the quarter equaled 1.8 times, compared to 2.0 times at the end of the previous quarter. With this financial review of the first quarter of 2025, I would like to hand the word back to Patrick for some concluding remarks.
Thank you. Carl. Johan. We live in a world and a geopolitical environment that continues to be uncertain with new developments almost every day. Vermion, however, is an attractive exposure to really resilient and, well, growing markets. The final outcome of the tariffs is yet to be seen. We're monitoring this very closely, as is the rest of the world. Based on what we know today, it will have a limited impact on our full year earnings. We continue to execute on our strategy of building a company with leading positions in attractive global niches in the animal health market. We're well positioned in an uncertain world. We have great confidence in our strategy and our ability to navigate a changing landscape throughout the rest of the year and in the future. With that said, we can open up for Q&A.
Ask a question. Please. Dial the pound key on your telephone keypad to enter the queue. If you wish to withdraw your question, please dial the pound key on your telephone keypad. The next question comes from Kavya from UBS. Please go ahead.
Good morning. Thank you for taking my questions. I've just got two, please. The first one is on tariffs. I appreciate that you mention there's a limited impact on earnings this year. Would you be able to give us some more details, please, on what you have baked into your assumptions so far? And then the second one was on Specialty Pharma. So very strong organic growth is evident, mainly because it's still the largest therapeutic area. Could you give us a sense of how strong nutrition growth was in the quarter, please? And then just as a follow-up, cross-selling seems to be a lower proportion of organic growth this quarter. And when I back it out on my maps, the absolute revenue contribution from cross-selling was down fairly significantly versus last year. Would you be able to provide some insight on this, please? Thank you.
Uh, morning. And let me start to give some color on tariffs. And then Patrick can speak a little bit more on specialty pharma. So on tariffs. And of course, we're monitoring the situation closely, and it's still uncertain how this will pan out in the end and where we will ultimately end up, considering the current situation and the tariffs as they stand at the moment. Roughly half of our sales in the US are impacted by tariffs, and as a consequence, we expect a limited impact on adjusted EBITDA for the full year of 2025. And when we say a limited impact, that's sort of a low single-digit percentage point on adjusted EBITA as the tariffs stand currently. And also, it's important to point out that we're looking into how the impact from the tariffs can be mitigated, depending on the final outcome, which could involve a mix of reshoring, supply chain adjustments, supply negotiations, price adjustments, and other activities that we're considering.
Yeah. Thank you. And maybe I can take the second question on Specialty Pharma and provide a little bit of color on where the different growth contributions are coming from. So maybe the highest growth in that segment is coming from the specialty pharmaceutical compounding business. It demonstrated yet another phenomenal quarter with outstanding performance. So that part of the business is continuing to have strong momentum. And there is nothing that we see that will stop that momentum from going. And that grows well over the average of specialty pharma as a segment. Um, dermatology and allergy together, uh, are at fleet average, if you like. It's a nice, healthy double-digit growth. And where we see a little bit of slower growth is in our specialized nutrition business, which, just for reference, was doing incredibly well in the fourth quarter. So as we mentioned, there are quarters where some of these businesses are delivering phenomenal growth. And then you have maybe a quarter where it is less stellar from a growth standpoint. So it's a little bit up and down there. Then, the cross-selling is actually also related to that situation. It's an order timing that is actually driving cross-selling down. And there's been a delay of one particular large order that we're getting into the second quarter here. So I expect the cross-selling to come back and rebound to the levels that we have seen historically.
And specifically, I just want to clarify on your calculations, there's still a positive contribution from cross-selling. It contributed to a fourth of the growth in the segment for the quarter, which, yes, is a little bit lower than what we've seen, being around a third in the quarter. So 2025. But to Patrick's point, that was more about timing than anything else. So it continued good momentum and growth support from the cross-selling initiative.
Understood. Thank you very much.
The next question comes from Sten Gustafson from ABG Sundal Collier. Please go ahead.
Good morning everyone. Um, so my first question would be on the MedTech business, in particular, the US. Uh, part of that, if you could talk a little bit about the growth outlook for the year given the current situation in the US, if you could provide us with any color on what you expect the US market to deliver in terms of growth for the year. Now that we're at least what it sounds like, done with the AOP. Part of the business, that would be my first question. And the second one would be a follow-up on the tariff question. I'm not sure if I fully got the numbers right there in terms of how much of the US sales is impacted by tariffs. Um, but that would obviously be helpful if you could give us some sort of details on the shipments in and out of the US. Um. For you. Thank you.
Yeah. Let me, uh, thank you for the questions. Let me start with your first question, and I'll call on you. We'll cover the second one. Um, so when you talk about the MedTech segment, now we have two parts. One is on Orthopaedics and the other one is on dental. So I'm talking about the orthopedic market business now. And I believe that's where you intended to focus your question as well. In the first quarter, our assessment of the market was that it shrank by low single digits. And we follow that market or perform slightly better than the market. And if we were to think about what we expect to happen in the remainder of 2025, we don't foresee any improvement in the market in the second quarter, but we believe that we can enhance our performance in the second quarter and onwards so we can surpass the market growth. Uh, in, in our segment. And the reason why we believe that is that for quite a few quarters now, we have had an outsized effort to educate and train a vast number of clinicians on the procedures, and we're reaching new customers this way. Although their volume may not be exceptionally high exactly when they are trained, we've built a relationship with them. When they start to see more customers come through in their clinics, and there are more of them being able to perform. We believe that will help us drive growth above where the market is. Maybe Kal will elaborate on the.
Yeah, just clarity on tariffs. And, uh, I said as it stands now with the current tariffs, roughly half of our US sales are subject to tariffs. And I said on the sales being subject to tariffs, we see a limited impact for the full year, low single digits, and an impact that we believe we can further mitigate with actions that we will implement.
Okay. Excellent. Thank you very much.
Question comes from Kavya from UBS. Please go ahead.
Sorry. Just a quick follow-up from me on the MedTech business. Just given the wording around this being the final phase-out of the annual order program. Could I check that this is definitely the last year you would expect AOP reductions to impact organic growth in MedTech? Please. And would you be able to quantify for us what the reduction in the AOP program and the AOP was this quarter, please? I believe it represents about €5.5 million of revenues in the prior year. Thank you.
Yeah. Yes, I'd be happy to. Yeah, I can confirm that. It's the last quarter that we will talk about. AOP. And just as a recap, we changed this program in Q1 last year and we changed it kind of mid-quarter and have been consistent, I think, with saying that this is the quarter where we're going to do the last tail of it. And so AOP is over now. So we have a normalized business with steady order flows, where all of the 12-month orders are now either converted into monthly or quarterly orders. We still have a few customers that, you know, desire to do full 12-month orders, but, um, that's up to them. And it’s not up to us to tell them what to do. It's their choice. And the impact in the first quarter was EUR 3 million.
Yeah, just clarity on tariffs.
The next question comes from Richard Andrew from Handelsbanken. Please go ahead.
Good morning, and thank you for taking my questions. Um, starting off, it would be interesting to hear a little bit high level on how you're thinking or framing the year in terms of organic growth for the group. Obviously, you had a strong performance excluding the MedTech headwind here in Q1. In the remaining business areas, do you still feel it's feasible to achieve that high single-digit type growth this year? Uh, or what's the working assumption on the group for the year? Would be interesting just to hear a little bit on the puts and takes for 2025. Thank you.
Yeah. Thanks for your question. Um, we're off to a good start. We knew it was going to be a little bit lower on organic growth because of the AOP program adjustments. But we feel very good about the full year numbers. So, um, in the range that you're indicating, we're comfortable with.
Very helpful. I noticed you observed quite a healthy margin development in vet services, I believe. In previous quarters, you indicated that we should expect some growth initiatives that might burden the margin. Um, just wanted to see and hear a little bit if we should expect an impact in the coming quarters there that might soften or dampen the margin development in vet services. I believe you also mentioned having some geographical tailwind from the geo mix in the quarter here as well.
Yeah, No, that's correct. And it continued with a strong and solid performance for veterinary services in the first quarter. Um, and as you mentioned, the margins were positively impacted by the continued strong growth. And, the sort of operational leverage in the business, there were some positive effects from mix, both from a geographical perspective, you could say in core versus clinics and, lastly, which will impact the margins slightly in the coming quarters. And to your point, yes, we are investing in new initiatives and geographical expansion in veterinary services to continue the great momentum we have in that segment. And that will weigh on margins in the coming quarters.
Okay. So, a little bit of a margin headwind to expect there going into the coming quarters then. Good to know. Um, and then final question from me would be interesting to hear a little bit more on the drivers of the growth in diagnostics. Uh, how much is coming from the venture into the companion animal segment and the durability of the growth and the margin trend you've seen with the sequential improvements in both growth and margins. Just trying to get a sense if this is a bit of a one-off or a sort of a new trajectory. You're on. Uh, how much is coming from the venture into the companion animal segment and the durability of the growth and the margin trend you've seen here with the sequential improvements in both growth and margins?
And now in Diagnostics, we start from the big picture. The growth in Diagnostics was supported by strong growth and momentum in all regions, and across all product areas where we see new customer acquisition and increased penetration from new products. So the growth in the quarter has been from a very broad perspective. There was some positive contribution to growth also from, you could say, outbreak-driven demand, but overall, the growth has been broad across diagnostics. And on your question regarding our diversifying the business towards companion animal diagnostics, that's an initiative that we are continuing. We're seeing a positive momentum in that initiative. But it is from a very low base. So the contribution in the first quarter from that, in terms of revenue, is still very limited.
Uh, how much is it coming from the, um, sort of venture into the companion animal segment, and what is the sort of durability of the growth and the margin trend you've seen here with the sequential improvements in both growth and margins? Claire, thanks for taking my questions.
The next question comes from Arvid Nycander from Carnegie. Please go ahead.
Good morning and thanks for taking my questions. So just a couple of follow-ups on tariffs. Uh, so if relocating production to the US proves the most viable option, uh, how long do you estimate that transition would take for you to complete? And secondly, on M&A, what impact, if any, do tariffs and geographical geopolitical uncertainty have on your ambitions for 2025? Have any of your more advanced processes been aborted or delayed due to the targets relying on production outside the US? The US, for example, is the broader macroeconomic uncertainty also a reason to be more cautious in the near term? Um, I understand that there are lots of moving parts here, of course, but it would be very interesting to hear your thoughts.
Um, I think I'm going to leave the tariff question for Carl Johan. But I'll cover the M&A and the near term here. Um, just look at what we did here in the first quarter. We acquired one business. It was located in the US. We also, in our vet services business, built up this DVM growth initiative to further penetrate the market in America. Um, so, of course, we're very interested in expanding our business all across the globe, and America is part of that. And it's also the biggest animal health market in the world. So we continue to make investments there. Um, as we have planned in the past, I think what's going on now can be an opportunity for us, and I feel very good about our business. I feel very good about how stable it is and where we can go. And as other people might be more nervous than we are, that provides an opportunity for us to maybe actually go acquire more businesses that we can incorporate into our company, provided they have a good strategic fit and potential for value creation. Um, so we don't see any aborted processes or anything like that. On the contrary, there are some sellers who might want to accelerate their pace of selling to avoid further uncertainty in the future. Um, but, um, I feel that we have a good strategy. We're well positioned, we have a good execution model, and we have discipline on our M&A. All those are good things for us going into this uncertain world.
And on the tariffs. And I think, as you said, of course, there are a lot of different parts in that. I think, one, it's important to point out that there are other activities we will implement and that we're looking into to mitigate the impact from tariffs. So reshoring supply chain is one of many activities, definitely not the only activity that we're looking into in terms of reshoring. You could say supply chain. And that's also depending on which segment and sort of which therapeutic area we're talking about in the different segments that will give you sort of a slightly different answer. And we could also see the reshoring part of the supply chain. So it doesn't necessarily have to mean that we're moving the entire production or everything in the supply chain to the US. That could be a part of the supply chain that we move to the US to reduce tariffs. I think it's also important to say, of course, that we're monitoring the situation closely because we don't want to make any actions or decisions in the near term that might not be the best decision long term. Hence, we are monitoring the situation closely to ensure that we make the right long-term decisions for the business. But in short, there are certain areas where we can quite quickly reshore, you could say reshore, the supply chain to the US. And there are parts where that will be more of a midterm initiative for us to reshore production to the US, if we determine that's the best thing to do.
And it's also the biggest animal health market in the world. Thank you, guys. That's very helpful.
The next question comes from Adrian Elmlund from Nordica. Please go ahead.
Hi. Good morning. Um, a couple of questions from me here. Just firstly, a follow-up regarding the MedTech. Could you help us think about the organic growth going forward in terms of comparisons? Like, should we expect to see easier comps from Q2 now and onwards regarding the final reduction of the annual ordering program?
I think, um, the market, the underlying market, is likely going to be in the negative, showing low single-digit growth probably. And I think the way I think about our business is that we'll surpass that and we'll do so with anything between 200 and 600 basis points. So, possibly, low single digit in terms of the comps that we have.
Um, a couple of questions from me here. Perfect. Thank you. And a question here regarding the positive product mix in specialty pharma. Is this sustainable over the year or how should we think about the positive product mix going forward?
I think, as Patrick mentioned a little bit before, there will be some fluctuations between the quarters, so that mix could look a little bit different between quarters. But I think from a full-year perspective, we see positive momentum in all our therapeutic areas in Specialty Pharma. But maybe having said that, we've seen a very good performance and momentum in the specialized pharmaceuticals business within Specialty Pharma. I mentioned in the last two quarters that we have a very positive view on that therapeutic area within specialty pharma for the rest of the year as well. And they have a positive contribution from a mixed perspective on the margin.
Um, a couple of questions from me here. Perfect. Thank you. Um, lastly, it's very good to see increased operating cash flow. But could you give us some more guidance regarding the working capital that you expect throughout the year?
Yeah, sure. And as I think we've talked about before, working capital is one of the areas that we're focusing on to make sure that we continue to improve. Um, in terms of improving the operating cash flow, of course, we're working. We're sort of continuously working to make sure that we see increased operational leverage in the business and that we drive like-for-like margin improvement and, hence, increased profitability. In terms of working capital, we are especially focusing on inventory. There's some negative impact in the quarter due to tariffs, where we have increased inventory in specific areas to mitigate tariff impact and ensure that we reduce the impact from tariffs. So as we've mentioned before, now in the quarter, we saw working capital being 23% of revenue, and that's a number that will continue to slowly but steadily reduce throughout the year and over time.
Um, a couple of questions from me here. Perfect. Thank you for taking my questions. Um, have a good day.
Thank you. Thank you.
The next question comes from Marco Perez Cox from Barclays. Please go ahead.
Hi. Morning. Um, just one question for me. Um, also on the US MedTech business and your assumptions of market growth in Q2 and beyond, um, you speak about expecting the market to decline in low single digits. Uh, it would be great to just get more of an understanding of the building blocks and your rationale behind this, what you're seeing on the ground. I suppose, how much of the US MedTech business is out-of-pocket payments, and how much of a risk is there as we continue to see uncertainty in the US and the potential for markets to get worse? Um, do you see a risk of customers continuing or increasingly postponing here? And then just kind of as a follow on. Um, do you have any assumptions around customers postponing and how long a customer can actually postpone before it's no longer viable to bring their pet in for treatment? And actually, these are revenues that you've now lost, coming back as pent-up demand. Thank you.
Thanks. Um, we assess the market to grow or decline in low single digits. And, you know, it's not easy to predict what's going to happen in the future, obviously. But we don't think, um, it will get better in the second quarter. And that's driven by data that comes from consumer sentiment and some other sources. That is probably impacting how a US-based pet owner will react because 96% of dogs in the US are uninsured. So they would go out of pocket with that. So when the US consumer is more positive, they'll likely spend more money on this; it is our underlying hypothesis. Those general statistics are not showing improvement right now; however, that might change between now and the end of this year. Um, so our underlying assumption is that we will continue to see a low single-digit decline. Could it be worse? I think it could be worse if there is a large tariff implementation now and the dollar continues to weaken. Where's my dog's hip or my dog's knee? In that order of priority. And we observed that dog owners began to reprioritize that last summer. And they will likely continue to do so. And your question about what if I don't do it now is a good one. And they are elective, which means you don't have to do it. The dog will continue to live even if they don't get a new hip or a new knee on the hip side. You typically treat them with some sort of pain relief and can remain on pain medication until they pass away as a dog. Although you might live a better life if you get a new hip. The same is true for the knees. You don't have to do a knee repair or knee replacement. The dog will continue to limp and experience some pain because of it. As the dog ages, there is a benefit or return on performing the surgery. You can extend the life of the animal by doing these surgeries earlier, but if you think your dog has another six months to live, you're probably unlikely to make this investment. Although if it's five more years, I think you'll go and jump at it. All the dogs that are untreated now age. So it's a hard question to speculate about what's happening there, but it's clear that there are surgeries being postponed right now for sure. And we'll continue to do the education. And that's really our growth driver, where we bring new clinicians in who meet new dog owners who are unaware of this as a treatment alternative, because it's still an unknown procedure to solve the different problems that we have. And that's the reason why we believe we can grow, even if the market might be in a decline.
That's very clear. Thank you.
If you wish to ask a question, please dial the pound key. Five on your telephone keypad. For questions at this time. So I hand the conference back to the speakers for any closing comments.
Thank you very much for joining us today. And thank you for your questions. Um, we had a good first quarter. And, uh, we are optimistic about the remainder of the year. And we look forward to seeing you here in the middle of the summer to report our second quarter numbers. Enjoy the rest of the day. And thank you again.



















